Michael Richard Feldschuh Buys 3,360 Shares of Daxor Co. (NASDAQ:DXR) Stock

Daxor Co. (NASDAQ:DXR) CEO Michael Richard Feldschuh bought 3,360 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were acquired at an average cost of $7.68 per share, with a total value of $25,804.80. Following the purchase, the chief executive officer now directly owns 210,852 shares of the company’s stock, valued at approximately $1,619,343.36. This represents a 1.62 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Daxor Stock Up 4.7 %

Shares of NASDAQ DXR opened at $8.16 on Thursday. Daxor Co. has a fifty-two week low of $6.55 and a fifty-two week high of $10.00. The company has a 50 day simple moving average of $7.76 and a two-hundred day simple moving average of $8.49.

Hedge Funds Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC raised its holdings in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned 0.30% of Daxor worth $126,000 as of its most recent SEC filing. 1.34% of the stock is currently owned by institutional investors.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.